APhA encourages seniors to talk to pharmacists
WASHINGTON — The American Pharmacists Association is marking Older Americans Month by urging seniors to increase their knowledge about medications and wellness by talking to their pharmacists, the group said Monday.
The APhA said that as the most accessible healthcare providers and medication experts, pharmacists are ready to discuss issues that arise due to medications and age. This include helping seniors understand their medications and how to take them properly, the differences between branded and generic drugs, over-the-counter medications and herbal supplements and what kinds of side effects they might have, reading labels and dosing information and other topics.
The group also encourages consumers to fill their prescriptions at one pharmacy and get to know their pharmacist on a first-name basis.
Mylan’s generic Xibrom ophthalmic solution enters market
PITTSBURGH — Mylan has launched a generic drug for treating post-operative inflammation in patients who have undergone cataract extraction, the company said Monday.
Mylan announced the launch of bromfenac ophthalmic solution in the 0.09% strength, for twice-daily administration, under a development and supply agreement with Coastal Pharmaceuticals.
The drug is a generic version of ISTA’s Xibrom ophthalmic solution. Various versions of bromfenac ophthalmic solution had sales of about $116 million during the 12-month period ended in March, according to IMS Health.
Teva to acquire Taiyo
JERUSALEM — Generic drug maker Teva Pharmaceutical Industries will acquire a privately owned manufacturer of generic drugs based in Japan, Teva said Monday.
Teva announced the purchase of a 57% stake in Nagoya, Japan-based Taiyo Pharmaceutical Industry Co. for $460 million, with plans to extend its offer to purchase all remaining shares of the company.
Taiyo is Japan’s third-largest generic drug company, with sales of $530 million in 2010 and a product portfolio of more than 550 generic drugs, including injectables used in hospitals. Teva president and CEO Shlomo Yanai said the acquisition would position Teva as a leading player in Japan’s quickly growing generics market.